


Response to November 21, 2005 Office Action
 Serial No. 10/722,702
 CVT No. 01-157-CIP

APPENDIX A

CLEAN COPY OF THE CLAIMS

1. A compound of the formula:



Formula I

wherein:

R¹ is optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;

X is a covalent bond or optionally substituted alkylene;

R² is R⁴-Z-Y-C≡C- or optionally substituted pyrazolyl:

in which Y is optionally substituted alkylene, Z is oxygen, sulfur or -NH-, and R⁴ is optionally substituted aryl or optionally substituted heteroaryl; and

R³ is hydroxymethyl or -C(O)-NR⁵R⁶;

in which R⁵ and R⁶ are independently hydrogen or lower alkyl.

2. The compound of claim 1, wherein R² is optionally substituted pyrazol-1-yl.
3. The compound of claim 2, wherein R¹ is optionally substituted alkyl or optionally substituted aryl and R³ is hydroxymethyl.
4. The compound of claim 3, wherein R² is pyrazo-1-yl substituted by optionally substituted lower alkyl, ester, aminocarbonyl, optionally substituted aryl, or optionally substituted heteroaryl.

Response to November 21, 2005 Office Action
Serial No. 10/722,702
CVT No. 01-157-CIP

5. The compound of claim 4, wherein pyrazol-1-yl is substituted by optionally substituted phenyl or optionally substituted benzyl.
6. The compound of claim 5, wherein R^1 is optionally substituted lower alkyl and X is a covalent bond.
7. The compound of claim 6, wherein R^1 is methyl and R^2 is 4-(4-methoxyphenyl)pyrazol-1-yl, namely (4S,2R,3R,5R)-5-(hydroxymethyl)-2-{2-[4-(4-methoxyphenyl)pyrazolyl]-6-(methylamino)purin-9-yl}oxolane-3,4-diol.
8. The compound of claim 6, wherein R^1 is n-propyl and R^2 is 4-(4-methoxyphenyl)pyrazol-1-yl, namely (4S,2R,3R,5R)-5-(hydroxymethyl)-2-{2-[4-(4-methoxyphenyl)pyrazolyl]-6-(n-propylamino)purin-9-yl}oxolane-3,4-diol.
9. The compound of claim 6, wherein R^1 is methyl and R^2 is 4-(4-chlorobenzylaminocarbonyl)pyrazol-1-yl, namely (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(methylamino)purin-2-yl}pyrazol-4-yl)-N-(4-chlorophenyl)carboxamide.
10. The compound of claim 6, wherein R^1 is methyl and R^2 is 4-(4-chlorobenzylaminocarbonyl)pyrazol-1-yl, namely (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(methylamino)purin-2-yl}pyrazol-4-yl)-N-(4-chlorophenyl)carboxamide.
11. The compound of claim 4, wherein R^2 is pyrazo-1-yl substituted by optionally substituted heteroaryl.
12. The compound of claim 11, wherein R^1 is n-propyl and R^2 is 4-(pyridin-2-yl)pyrazol-1-yl, namely (4S,2R,3R,5R)-5-(hydroxymethyl)-2-[4-(pyridin-2-yl)pyrazolyl]-6-(n-propylamino)purin-9-yl}oxolane-3,4-diol.

Response to November 21, 2005 Office Action

Serial No. 10/722,702

CVT No. 01-157-CIP

13. The compound of claim 5, wherein R^1 is optionally substituted aryl and X is alkylene.
14. The compound of claim 13, wherein R^1 is 3-iodobenzyl and R^2 is 4-(4-methoxyphenyl)pyrazol-1-yl, namely (4S,2R,3R,5R)-5-(hydroxymethyl)-2-{2-[4-(4-methoxyphenyl)pyrazolyl]-6-(3-iodobenzylamino)purin-9-yl}oxolane-3,4-diol.
15. The compound of claim 1, wherein R^2 is optionally substituted pyrazol-4-yl.
16. The compound of claim 15, wherein R^1 is optionally substituted alkyl or optionally substituted aryl, R^3 is hydroxymethyl, and X is a covalent bond.
17. The compound of claim 16, wherein R^1 is methyl, R^2 is 1-benzylpyrazol-4-yl, R^3 is hydroxymethyl, and X is a covalent bond, namely (4S,2R,3R,5R)-5-(hydroxymethyl)-2-{2-[1-benzylpyrazolyl]-6-(methylamino)purin-9-yl}oxolane-3,4-diol.
18. The compound of claim 16, wherein R^1 is n-propyl, R^2 is 1-benzylpyrazol-4-yl, R^3 is hydroxymethyl, and X is a covalent bond, namely (4S,2R,3R,5R)-5-(hydroxymethyl)-2-{2-[1-benzylpyrazolyl]-6-(n-propylamino)purin-9-yl}oxolane-3,4-diol.
19. The compound of claim 1, wherein R^2 is $R^4-Z-Y-C\equiv C-$.
20. The compound of claim 19, wherein R^4 is optionally substituted phenyl and Y is alkylene of 1-3 carbon atoms.
21. The compound of claim 20, wherein R^4 is phenyl optionally substituted by methoxy or chloro, and Y is methylene.

Response to November 21, 2005 Office Action
Serial No. 10/722,702
CVT No. 01-157-CIP

22. The compound of claim 21, wherein R¹ is optionally substituted alkyl, X is a covalent bond, and R³ is hydroxymethyl.
23. The compound of claim 22, wherein R¹ is methyl, R⁴ is phenyl and Z is oxygen, namely 2-hydroxymethyl-5-[6-methylamino-2-(3-phenoxypropyn-1-yl)purin-9-yl]-tetrahydrofuran-3,4-diol.
27. A pharmaceutical composition comprising at least one pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of claim 1.